Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails

Shanghai Zhongshan Hospital1,320 enrolled

Overview

To observe and access the Effects and safety of terlipressin or high dose somatostatin/octreotide when usual dose somatostatin/octreotide fail to achieve hemostasis in patients with acute variceal bleeding.

The prognosis information of the patients with acute variceal bleeding will be collected, including hemostasis rate, early rebleeding rate, mortality, complications, severity adverse events, economic burdens and quality of life, when terlipressin or high dose somatostatin/octreotide is used as salvation to patients fail to achieve initial hemostasis.The results may help gastroenterologists to make decisions when administering vasoactive medicines to those suffered from acute variceal bleeding.

Study Type

OBSERVATIONAL

Enrollment

1,320

Conditions

Liver Cirrhosis Esophageal and Gastric Varices Hemorrhage

Interventions

TerlipressinDRUG

administered as a first-line medicine or as salvage

Usual Dose Somatostatin/OctreotideDRUG

administered as a first-line medicine or as salvage

High Dose Somatostatin/OctreotideDRUG

administered as salvage

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Cirrhosis patients admitted to Emergency Department because of acute variceal bleeding Exclusion Criteria: * No signs of variceal bleeding are found by endoscopy or portal hypertensive gastropathy is responsible for the bleeding * Patients undergo endoscopy after 72h from the beginning of acute variceal bleeding * Patients with hepatorenal syndrome * Patients with ischemia organic cardiopathy (including myocardial infarction or unstable angina pectoris) or myocardial ischemia indicated by ECG in the past 6 months * Patients allergic to/with contraindications of vasoactive drugs

Locations (1)

Zhongshan Hospital

Shanghai, Shanghai Municipality, China

RECRUITING